• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：全身化疗后使用S-1/卡培他滨对转移性鼻咽癌患者进行口服维持化疗：单机构经验[勘误]

Erratum: Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum].

出版信息

Cancer Manag Res. 2020 Mar 31;12:2365-2366. doi: 10.2147/CMAR.S252622. eCollection 2020.

DOI:10.2147/CMAR.S252622
PMID:32308475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7135955/
Abstract

[This corrects the article DOI: 10.2147/CMAR.S234271.].

摘要

[本文更正了文章的数字对象标识符：10.2147/CMAR.S234271。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40a4/7135955/8266f11f927d/CMAR-12-2365-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40a4/7135955/8266f11f927d/CMAR-12-2365-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40a4/7135955/8266f11f927d/CMAR-12-2365-g0001.jpg

相似文献

1
Erratum: Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum].勘误：全身化疗后使用S-1/卡培他滨对转移性鼻咽癌患者进行口服维持化疗：单机构经验[勘误]
Cancer Manag Res. 2020 Mar 31;12:2365-2366. doi: 10.2147/CMAR.S252622. eCollection 2020.
2
Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience.S-1/卡培他滨用于转移性鼻咽癌患者全身化疗后的口服维持化疗：单机构经验
Cancer Manag Res. 2020 Feb 25;12:1387-1396. doi: 10.2147/CMAR.S234271. eCollection 2020.
3
Erratum: Explore the Value of Adding Induction Chemotherapy to Concurrent Chemoradiotherapy in T3-4N0M0 Nasopharyngeal Carcinoma Patients: A Retrospective Study [Corrigendum].勘误：探索诱导化疗联合同步放化疗在T3-4N0M0鼻咽癌患者中的价值：一项回顾性研究[勘误]
Cancer Manag Res. 2022 May 27;14:1835-1836. doi: 10.2147/CMAR.S375850. eCollection 2022.
4
Erratum: The Development of a Nomogram to Predict Post-Radiation Necrosis in Nasopharyngeal Carcinoma Patients: A Large-Scale Cohort Study [Corrigendum].勘误：预测鼻咽癌患者放疗后坏死的列线图的开发：一项大规模队列研究[勘误]。
Cancer Manag Res. 2020 Feb 25;12:1371. doi: 10.2147/CMAR.S246689. eCollection 2020.
5
Erratum: Stanniocalcin 2 (STC2) Expression Promotes Post-Radiation Survival, Migration and Invasion of Nasopharyngeal Carcinoma Cells [Corrigendum].勘误：2型鲟钙蛋白（STC2）表达促进鼻咽癌细胞放疗后的存活、迁移和侵袭 [勘误说明]
Cancer Manag Res. 2019 Dec 11;11:10409. doi: 10.2147/CMAR.S240959. eCollection 2019.
6
Erratum: Comparative Study of Auto Plan and Manual Plan for Nasopharyngeal Carcinoma Intensity-Modulated Radiation Therapy [Corrigendum].勘误：鼻咽癌调强放射治疗自动计划与手动计划的比较研究[更正]
Cancer Manag Res. 2020 Dec 15;12:12851. doi: 10.2147/CMAR.S296533. eCollection 2020.
7
Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.口服维持化疗对转移性鼻咽癌的疗效及循环 EBV DNA 的预测价值
Cancer Med. 2020 Apr;9(8):2732-2741. doi: 10.1002/cam4.2926. Epub 2020 Feb 23.
8
Erratum: The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum].勘误：阿帕替尼治疗晚期滑膜肉瘤的疗效与安全性：单机构21例患者的病例系列 [更正]。
Cancer Manag Res. 2020 Sep 4;12:8079. doi: 10.2147/CMAR.S279244. eCollection 2020.
9
Erratum: Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma [Corrigendum].
Cancer Manag Res. 2021 Sep 10;13:7055-7056. doi: 10.2147/CMAR.S338286. eCollection 2021.
10
Erratum: Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma [Corrigendum].
Cancer Manag Res. 2021 Aug 31;13:6797-6798. doi: 10.2147/CMAR.S336175. eCollection 2021.